Abstract
We describe a 69-year-old man with refractory relapsing thrombotic thrombocytopenic purpura (TTP) successfully treated with rituximab. The patient had once been successfully treated with plasmapheresis and vincristine, but he had relapsed after a short period. Although plasmapheresis, vincristine, and splenectomy could not achieve a consistent elevation of the platelet count, rituximab administration provided sustained remission for more than 7 months. Rituximab should be considered as a therapeutic alternative for refractory TTP.
MeSH terms
-
ADAM Proteins
-
ADAMTS13 Protein
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Autoantibodies / blood
-
Disease-Free Survival
-
Humans
-
Male
-
Metalloendopeptidases / immunology
-
Purpura, Thrombotic Thrombocytopenic / drug therapy*
-
Purpura, Thrombotic Thrombocytopenic / immunology
-
Remission Induction
-
Rituximab
-
Salvage Therapy
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Autoantibodies
-
Rituximab
-
ADAM Proteins
-
Metalloendopeptidases
-
ADAMTS13 Protein
-
ADAMTS13 protein, human